Back to top

Image: Bigstock

Xylem (XYL) to Report Q3 Earnings: What's in the Offing?

Read MoreHide Full Article

Xylem Inc. (XYL - Free Report) is scheduled to release third-quarter 2019 results on Oct 31, before the market opens.

The company delivered weaker-than-expected results in one of the last four quarters, while recorded in-line results thrice. Average earnings surprise was a negative 2.59%. In the last reported quarter, the company’s earnings of 79 cents were in line with the Zacks Consensus Estimate.

In the past three months, shares of the water solutions provider have gained 3.6% compared with the industry’s growth of 0.7%.




Let us see how things are shaping up for Xylem this quarter.

Factors Affecting Q3 Performance

Xylem’s third-quarter results are expected to reflect gains from strengthening of the U.S. utility market, investments for product innovation and robust digital solutions business. Also, businesses in India and China are anticipated to have flourished in the quarter. Shareholder-friendly policies might have added more value to shareholder’s wealth in the quarter.

However, uncertain economic conditions might have hampered business in Latin America and Europe. Additionally, adverse impacts of unfavorable movements in foreign currencies, cost escalation due to tariffs, realignment initiatives and other inflationary pressures might have weighed on the company’s performance in the quarter.

For the to-be-reported quarter, Xylem anticipates organic sales growth of 4-5%, whereas it registered 8% in the year-ago quarter. On a segmental basis, organic sales are expected to grow 4-5% for the Water Infrastructure segment, 3-4% for Applied Water, and 5-6% for Measurement & Control Solutions. Adjusted operating margin is predicted to be 15-15.1%.

The Zack Consensus Estimate for the company’s earnings per share is pegged at 82 cents, indicating growth of 6.5% from the year-ago quarter’s reported figure. Also, the consensus estimate for revenues of $1,329 million suggests 3.3% rise from the year-ago quarter’s reported figure.

For the Water Infrastructure segment, the Zacks Consensus Estimate for revenues for the third quarter of 2019 is pegged at $560 million, suggesting a 3.5% improvement from that generated in the year-ago quarter.

Third-quarter revenue estimates for the Applied Water segment are pegged at $384 million, suggesting 1.6% growth from sales generated in the year-ago quarter. For the Measurement & Control Solutions segment, revenue estimates are pegged at $383 million, indicating 4.1% rise from the year-ago reported figure.

Earnings Whispers

Our proven model doesn’t conclusively predict an earnings beat for Xylem this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Earnings ESP: The company has an Earnings ESP of -0.71%.

Xylem Inc. Price, Consensus and EPS Surprise

 

Xylem Inc. Price, Consensus and EPS Surprise

Xylem Inc. price-consensus-eps-surprise-chart | Xylem Inc. Quote

Zacks Rank: Xylem currently carries a Zacks Rank #3.

Stocks to Consider

Here are some companies that you may want to consider as according to our model, these have the right combination of elements to post an earnings beat this quarter:

Plug Power, Inc (PLUG - Free Report) presently has an Earnings ESP of +58.33% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Sealed Air Corporation (SEE - Free Report) currently has an Earnings ESP of +2.40% and a Zacks Rank #3.

Welbeit, Inc has an Earnings ESP of +1.01% and a Zacks Rank #3 at present.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Sealed Air Corporation (SEE) - free report >>

Plug Power, Inc. (PLUG) - free report >>

Xylem Inc. (XYL) - free report >>

Published in